Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

PRIMARY OBJECTIVE: I. To determine if regional nodal radiation therapy prolongs the time to regional recurrence. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive adjuvant immunotherapy and nodal radiation therapy (30 Gy in 5 treatments over 2-2.5 weeks). GROUP II: Patients receive adjuvant immunotherapy alone. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

The Role of Nodal Radiation Therapy in Sentinel Lymph Node Positive Melanoma

This phase III trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Patients with a positive inguinal node will be excluded due to increased risk of radiation-associated toxicity at this site. Prior studies of patients with more advanced melanoma have shown nodal radiation therapy can decrease the risk of nodal recurrence but it is not known if this same benefit will be seen in patients with high risk sentinel lymph node positive disease who are planned for immunotherapy.

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

Recruitment

Summary

Participation Requirements

Description

Tracking Information